Investment Bank Rothschild Indicates Several Strong Points Of Cash-strapped Wockhardt
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian pharmaceutical and biotechnology company Wockhardt may be finding itself in an extremely tight financial condition due to its commitment to repay $110 million foreign currency convertible bonds by October and debts of more than $600 million it took for overseas acquisitions; however analysts remain upbeat on company strengths
You may also be interested in...
With Large Biosimilars Opportunity In Sight, Multinational Companies Open Dialogue With India’s Wockhardt
MUMBAI - Adversities are throwing up unexpected opportunities for the debt-ridden Indian drug maker Wockhardt. While the company is being helped to tide over its unprecedented financial crisis of $600 million in debts by a group of large Indian banks, strategic opportunities in its biotech businesses have now come to surface
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).